The Science of AntiMir

Revolutionizing Neurological Disease Treatment with a Dual Approach to Gene Therapy

Addressing the Root Cause of Proteinopathies

Neurological disorders often arise from proteinopathies, characterized by the accumulation of misfolded proteins in the brain. These misfolded proteins disrupt cellular processes, leading to neuronal death and the progressive decline in cognitive and motor functions. Canary’s dual-combination therapy targets the root cause of proteinopathies by employing two distinct yet synergistic mechanisms:

1. Vectorized Antibodies:

Our proprietary vectorized antibodies are designed to specifically bind and neutralize misfolded proteins, preventing their aggregation and toxicity. These antibodies are engineered to cross the blood-brain barrier, ensuring effective delivery to the affected areas of the brain.

2. Functional Transgene Replacement:

We utilize gene therapy to replace defective genes with functional copies, correcting the genetic abnormalities that underlie protein misfolding. This approach restores the production of normal proteins, halting the progression of disease and promoting cellular repair.

AntiMirs

AntiMirs are short RNA molecules that are designed to bind to and inhibit the function of miRNAs. They can be used to treat diseases that are caused by the overexpression of miRNAs.

AntiMirs can be delivered to cells in a variety of ways, including

Intravenous injection
This is the most common method of delivering AntiMirs
Intramuscular injection
This method is used when the target cells are located in the muscle tissue
Intranasal delivery
This method is used to deliver AntiMirs to the cells in the nose and throat
Inhalation
This method is used to deliver AntiMirs to the lungs
Topical delivery
This method is used to deliver AntiMirs to the skin

Canary's AlloMir gene-silencing platform can be leveraged to investigate a variety of diseases and conditions

Cancer

Viral infections

Autoimmune diseases

Genetic diseases

Neurological diseases

Advantages of AntiMir technology

Stability

AntiMirs are more stable than siRNAs. This is because they are single-stranded RNA molecules, while siRNAs are double-stranded RNA molecules. Double-stranded RNA molecules are more easily degraded by enzymes in the bloodstream and tissues.

Specificity

AntiMirs can be designed to be more specific than siRNAs. This is because they can be designed to bind to a specific miRNA, while siRNAs can bind to a range of miRNAs.

Safety

AntiMirs may be safer than siRNAs. This is because they are less likely to trigger an immune response.

AntimicroRNA (AntiMir) therapeutics have several potential advantages over siRNA therapeutics:

Broader therapeutic application

AntiMIR's can target a wider range of genes than siRNAs, as they can be designed to mimic the binding sequences of endogenous miRNAs, which regulate the expression of hundreds or even thousands of genes. This makes AntiMIR's more attractive for the treatment of complex diseases with multiple genetic components.

More potent gene silencing

AntiMIR's are more potent gene silencing agents than siRNAs, as they can trigger the degradation of multiple target mRNAs simultaneously. This is because AntiMIR's can bind to multiple miRNA-binding sites on a target mRNA, while siRNAs can only bind to one site.

Reduced off-target effects

AntiMIR's are less likely to have off-target effects than siRNAs, as they are designed to mimic the binding sequences of endogenous miRNAs. Endogenous miRNAs are highly conserved, which means that their binding sequences are very similar between different cell types and tissues. This reduces the risk of AntiMIR's binding to and silencing unintended genes.

More stable in vivo

AntiMIR's are more stable in vivo than siRNAs, as they are less likely to be degraded by nucleases. This is because AntiMIR's are more resistant to cleavage by Dicer, the enzyme that cleaves double-stranded RNA into siRNAs.

Pioneering Gene and RNA Therapy

We are revolutionizing healthcare by harnessing the power of cutting-edge RNA and gene therapies to develop and deliver innovative treatments that improve the lives of individuals and families. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.

Disclaimer: Canary Cure Therapeutics Inc’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized